Watch the video
We expected continued choppy waters in healthcare deals for two primary reasons: 1. functional reductions in Medicare Advantage reimbursement rates, and 2. a growing political consensus against private equity in healthcare.
Transcript
Let’s talk about healthcare. There are some things I think we need to discuss. The reality is that healthcare M&A is, in my opinion, at an inflection point. Like any other industry, it’s experienced the challenges of a high interest rate environment, and a lot of private equity firms have really struggled to hit the same multiples they were offering, sometimes extremely high multiples, just a couple of years before.
But I do think there are two headwinds we really need to take into consideration. First and foremost, the Medicare Advantage landscape appears to be shifting to a much more negative tone. We have a reduction in reimbursement rates that many of the different payers are assuming, sometimes up to 15%, when over the past 20 years we’ve assumed increases every year.
The second aspect is that one of the few things both Republicans and Democrats can agree on is that they’re not comfortable with private equity in healthcare. If you look at the New York Times articles, and articles in various other publications and news sources, the reality is that there’s growing pressure to limit the availability of private equity in healthcare.
This transcript was lightly edited for readability: filler words removed and paragraphs added; the meaning is unchanged. Market conditions and figures are as of the recording date. General education, not legal, tax, or investment advice.